Restart Life Sciences stock analysis
Want to see TSE:HEAL full AI Analyst Report?
Restart Life Sciences (HEAL) Stock Price & Analysis
HEAL Stock Chart & Stats
- Day’s Range
- CAD 0.07 - CAD 0.07
- 52-Week Range
- CAD 0.07 - CAD 0.14
- Previous Close
- CAD 0.07
- Volume
- N/A
- Average Volume (3M)
- 53.13K
- Market Cap
- CAD 4.06M
- Enterprise Value
- CAD 4.75M
- Total Cash (Recent Filing)
- CAD 762.36K
- Total Debt (Recent Filing)
- CAD 348.35K
- Price to Earnings (P/E)
- ―
- Beta
- 0.09
- Next Earnings
- Dec 02, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Improved 2025 Equity Position
The return to positive equity improves the company’s financial foundation and reduces the immediate strain associated with an impaired capital base. Although historical volatility remains a concern, this stabilization may support financing access and provide greater flexibility for future operations.
Modest Leverage
Relatively low debt compared with equity limits fixed financial obligations and reduces the burden of interest or principal payments. This gives management more flexibility to allocate capital toward developing the business and provides some resilience if operating performance remains weak.
Improving Cash-burn Trend
The reduction in cash outflow from earlier trough years indicates some improvement in cash management or operating requirements. While the company is not yet self-sufficient, a less severe burn rate could extend available funding and provide more time to establish sustainable operations.
Bears Say
No Recurring Revenue Base
The absence of recurring revenue means the company has not demonstrated commercial traction or a dependable source of operating income. Without a proven revenue base, funding must support development before customer economics can be validated, increasing execution risk over the coming quarters.
Persistent Operating Losses
Recurring operating losses show that the current business model is not covering its ongoing cost base. The lack of improvement in core profitability limits internal reinvestment capacity and leaves future financial progress dependent on achieving meaningful revenue growth or reducing expenses.
Continued Reliance On External Capital
Negative operating and free cash flow indicate that the company cannot currently fund its activities from internally generated cash. Continued dependence on outside financing can dilute existing holders, constrain strategic choices, and increase vulnerability if capital becomes harder to secure.
Restart Life Sciences News
HEAL FAQ
What was Restart Life Sciences’s price range in the past 12 months?
What is Restart Life Sciences’s market cap?
When is Restart Life Sciences’s upcoming earnings report date?
How were Restart Life Sciences’s earnings last quarter?
Is Restart Life Sciences overvalued?
Does Restart Life Sciences pay dividends?
What is Restart Life Sciences’s EPS estimate?
How many shares outstanding does Restart Life Sciences have?
What happened to Restart Life Sciences’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Restart Life Sciences?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Restart Life Sciences
Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder, the development of health-promoting foods designed for comprehensive mind and body wellness, and the execution of a psilocybin clinical trial aimed at fragile X syndrome. Founded in 2004 and based in Vancouver, Canada, the company adopted its current name in November 2024, having previously been known as Nova Mentis Life Science Corp.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Steve Loutskou
- Employees
- 3
- Website
- www.restartlife.co
- Address
- 700-838 West Hasting Street, Vancouver, BC, V6C 0A6, CA
Restart Life Sciences (HEAL) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 4 | 13 |
| Technical Analysis | 5 | 4 | 1 |
| Moving Averages | 0 | 0 | 12 |




